The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) from Elite Pharmaceuticals Inc (OTCBB: ELTP) for its methadone hydrochloride 5 mg and 10 mg tablets, the company revealed on Monday.
Glenmark Pharmaceuticals Inc (NSE: GLENMARK), Elite's marketing alliance partner, will sell and distribute the product, paying Elite manufacturing and licence fees.
Methadone is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate.
The drug can also be used for maintenance treatment of opioid addiction (heroin or other morphine-like drugs) in conjunction with appropriate social and medical services.
Annual retail sales for brand and generic methadone products are approximately USD30m, according to QuintilesIMS Health data.
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment